{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:18:57Z","timestamp":1794345537641,"version":"4.9.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omtn.2023.102084","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T04:47:27Z","timestamp":1700801247000},"page":"102084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies"],"prefix":"10.1016","volume":"35","author":[{"given":"Zhiguo","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2529-8785","authenticated-orcid":false,"given":"Ornit","family":"Chiba-Falek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.102084_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: clinical and pathological implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch. Neurol."},{"issue":"Suppl 6","key":"10.1016\/j.omtn.2023.102084_bib2","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/mds.10559","article-title":"Clinical overview of the synucleinopathies","volume":"18","author":"Mart\u00ed","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2023.102084_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1353-8020(99)00031-0","article-title":"Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies","volume":"5","author":"Spillantini","year":"1999","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Suppl 6","key":"10.1016\/j.omtn.2023.102084_bib4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.10557","article-title":"Neuropathological spectrum of synucleinopathies","volume":"18","author":"Jellinger","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2023.102084_bib5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2023.102084_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.biochem.74.082803.133400","article-title":"The biochemistry of Parkinson's disease","volume":"74","author":"Cookson","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omtn.2023.102084_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1087753","article-title":"Molecular pathways of neurodegeneration in Parkinson's disease","volume":"302","author":"Dawson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtn.2023.102084_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.omtn.2023.102084_bib9","first-page":"1939","article-title":"Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia","volume":"261","author":"Grothe","year":"2014","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtn.2023.102084_bib10","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awu193","article-title":"Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease","volume":"137","author":"Hall","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2023.102084_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-510X(02)00006-0","article-title":"Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies","volume":"195","author":"Marui","year":"2002","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.omtn.2023.102084_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","article-title":"Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction","volume":"117","author":"Beach","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtn.2023.102084_bib13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00439-008-0582-9","article-title":"Genomewide association study for susceptibility genes contributing to familial Parkinson disease","volume":"124","author":"Pankratz","year":"2009","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2023.102084_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0404.2008.01019.x","article-title":"Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population","volume":"118","author":"Myhre","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.omtn.2023.102084_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.mad.2007.04.002","article-title":"Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease","volume":"128","author":"Ross","year":"2007","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.omtn.2023.102084_bib16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.20268","article-title":"alpha-Synuclein promoter confers susceptibility to Parkinson's disease","volume":"56","author":"Pals","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2023.102084_bib17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.20438","article-title":"Multiple regions of alpha-synuclein are associated with Parkinson's disease","volume":"57","author":"Mueller","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2023.102084_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/hmg\/ddl030","article-title":"Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease","volume":"15","author":"Mizuta","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2023.102084_bib19","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1212\/01.wnl.0000275524.15125.f4","article-title":"{alpha}-Synuclein and Parkinson disease susceptibility","volume":"69","author":"Winkler","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2023.102084_bib20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ng.485","article-title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease","volume":"41","author":"Satake","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2023.102084_bib21","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Sim\u00f3n-S\u00e1nchez","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2023.102084_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.296.6.661","article-title":"Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease","volume":"296","author":"Maraganore","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2023.102084_bib23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2023.102084_bib24","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1093\/hmg\/ddu334","article-title":"Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies","volume":"23","author":"Bras","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2023.102084_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10048-016-0478-0","article-title":"Up-regulation of SNCA gene expression: implications to synucleinopathies","volume":"17","author":"Tagliafierro","year":"2016","journal-title":"Neurogenetics"},{"key":"10.1016\/j.omtn.2023.102084_bib26","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/mds.21007","article-title":"Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients","volume":"21","author":"Chiba-Falek","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2023.102084_bib27","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1093\/hmg\/ddu196","article-title":"The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease","volume":"23","author":"Linnertz","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2023.102084_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jalz.2015.05.011","article-title":"A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression","volume":"11","author":"Lutz","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.omtn.2023.102084_bib29","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1093\/nar\/gkn084","article-title":"Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease","volume":"36","author":"Gr\u00fcndemann","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.102084_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0006-8993(01)02772-X","article-title":"Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease","volume":"914","author":"Rockenstein","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.omtn.2023.102084_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012122","article-title":"Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra","volume":"5","author":"McCormack","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.102084_bib32","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1038\/mtna.2015.14","article-title":"Normalization of Overexpressed alpha-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference","volume":"4","author":"Takahashi","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.102084_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112413","article-title":"Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication","volume":"9","author":"Flierl","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.102084_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2017.04.004","article-title":"Deregulation of alpha-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA","volume":"154","author":"Guhathakurta","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.omtn.2023.102084_bib35","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","article-title":"Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains","volume":"30","author":"Jowaed","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtn.2023.102084_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cns.12059","article-title":"A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons","volume":"19","author":"Wang","year":"2013","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.omtn.2023.102084_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015522","article-title":"CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease","volume":"5","author":"Matsumoto","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.102084_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.652226","article-title":"Cell-Type Specific Changes in DNA Methylation of SNCA Intron 1 in Synucleinopathy Brains","volume":"15","author":"Gu","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtn.2023.102084_bib39","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102084_bib40","article-title":"Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models","volume":"145","author":"Tagliafierro","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omtn.2023.102084_bib41","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41592-018-0048-5","article-title":"An enhanced CRISPR repressor for targeted mammalian gene regulation","volume":"15","author":"Yeo","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2023.102084_bib42","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtn.2023.102084_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ana.410350110","article-title":"Autosomal dominant Lewy body parkinsonism in a four-generation family","volume":"35","author":"Waters","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2023.102084_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026159","article-title":"SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress","volume":"6","author":"Byers","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.102084_bib45","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1007\/s00018-011-0770-y","article-title":"Specification of neuronal and glial subtypes from human pluripotent stem cells","volume":"68","author":"Liu","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2023.102084_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cm.970170207","article-title":"The expression and posttranslational modification of a neuron-specific beta-tubulin isotype during chick embryogenesis","volume":"17","author":"Lee","year":"1990","journal-title":"Cell Motil Cytoskeleton"},{"key":"10.1016\/j.omtn.2023.102084_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0165-3806(94)00139-1","article-title":"Age and differentiation-related differences in neuron-specific tubulin immunostaining of olfactory sensory neurons","volume":"83","author":"Lee","year":"1994","journal-title":"Brain Res. Dev. Brain Res."},{"key":"10.1016\/j.omtn.2023.102084_bib48","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1523\/JNEUROSCI.14-09-05399.1994","article-title":"Expression of neuron-specific tubulin defines a novel population in the proliferative layers of the developing telencephalon","volume":"14","author":"Menezes","year":"1994","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtn.2023.102084_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11055-008-0025-z","article-title":"Nestin in central nervous system cells","volume":"38","author":"Gilyarov","year":"2008","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.omtn.2023.102084_bib50","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0092-8674(90)90662-X","article-title":"CNS stem cells express a new class of intermediate filament protein","volume":"60","author":"Lendahl","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2023.102084_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02741387","article-title":"Tyrosine hydroxylase and Parkinson's disease","volume":"16","author":"Haavik","year":"1998","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.omtn.2023.102084_bib52","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1046\/j.1440-1827.1999.00977.x","article-title":"Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system","volume":"49","author":"Oda","year":"1999","journal-title":"Pathol. Int."},{"key":"10.1016\/j.omtn.2023.102084_bib53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/hmg\/ddy355","article-title":"Multiplication of the SNCA locus exacerbates neuronal nuclear aging","volume":"28","author":"Tagliafierro","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2023.102084_bib54","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jalz.2017.03.001","article-title":"Genetic analysis of alpha-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies","volume":"13","author":"Tagliafierro","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.omtn.2023.102084_bib55","article-title":"All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders","author":"Kantor","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2023.102084_bib56","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2023.102084_bib57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"alpha-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omtn.2023.102084_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.947191","article-title":"The relationship of alpha-synuclein to mitochondrial dynamics and quality control","volume":"15","author":"Thorne","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtn.2023.102084_bib59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In\u00a0vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2023.102084_bib60","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2021.01.001","article-title":"The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models","volume":"29","author":"MacDougall","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102084_bib61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41467-020-20440-5","article-title":"A logical network-based drug-screening platform for Alzheimer's disease representing pathological features of human brain organoids","volume":"12","author":"Park","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102084_bib62","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In\u00a0vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102084_bib63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2011.04.036","article-title":"An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons","volume":"1395","author":"Khodr","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.omtn.2023.102084_bib64","first-page":"56915","article-title":"A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR\/Cas9-mediated Gene Knockout in Dividing Cells","volume":"130","author":"Vijayraghavan","year":"2017","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omtn.2023.102084_bib65","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2016.05.022","article-title":"Molecular Features Underlying Neurodegeneration Identified through In\u00a0Vitro Modeling of Genetically Diverse Parkinson's Disease Patients","volume":"15","author":"Lin","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2023.102084_bib66","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.scr.2013.08.002","article-title":"Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling","volume":"11","author":"Crompton","year":"2013","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.omtn.2023.102084_bib67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.14715\/cmb\/2021.67.1.22","article-title":"Phytochemical investigation and effective therapeutic potential of plants extracts against breast and ovarian cancer cell lines: compounds from zizyphus mauritiana and triticum aestivum","volume":"67","author":"Tabassam","year":"2021","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.omtn.2023.102084_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24071380","article-title":"In\u00a0Vitro and in Silico Evaluation of Bikaverin as a Potent Inhibitor of Human Protein Kinase CK2","volume":"24","author":"Haidar","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2023.102084_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143458","article-title":"Core-Clock Genes Regulate Proliferation and Invasion via a Reciprocal Interplay with MACC1 in Colorectal Cancer Cells","volume":"14","author":"Basti","year":"2022","journal-title":"Cancers"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123003025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123003025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:40:22Z","timestamp":1760856022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123003025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2162253123003025"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102084","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"102084"}}